Effects of bevacizumab administration on the hypoxia - induced pulmonary hypertension rat model
Autor: | Duygu Gürel, Eyüp Sabri Uçan, Ali Necati Gökmen, Canan Cicek Demir, Osman Yilmaz, Şadiye Canan Çoker, Meral Karaman, Yasemen Adali |
---|---|
Rok vydání: | 2021 |
Předmět: |
Vascular Endothelial Growth Factor A
Bevacizumab genetic structures pulmonary Hypertension Pulmonary Pharmacology Article Neovascularization chemistry.chemical_compound Right ventricular hypertrophy Medicine Animals Rats Wistar Lung Neovascularization Pathologic business.industry hypoxia General Medicine Hypoxia (medical) medicine.disease Pulmonary hypertension eye diseases Rats Vascular endothelial growth factor medicine.anatomical_structure chemistry Hypertension Ventricular pressure medicine.symptom business medicine.drug |
Zdroj: | Turkish Journal of Medical Sciences |
ISSN: | 1303-6165 |
Popis: | Background/aim: Bevacizumab is a chemotherapeutic drug, which selectively binds to vascular endothelial growth factor (VEGF) and mainly inhibits angiogenesis and neovascularization. We aimed to study the possible effects of bevacizumab on right ventricular pressure (RVP), right ventricular hypertrophy, and VEGF, in hypoxia -induced pulmonary hypertension (PH) rat model. Materials and methods: 24 adult Wistar Albino rats were randomly divided into four groups: control group -saline; Bevacizumab Group; PH Group; PH + Bevacizumab Group. In hypoxia -induced model, 10% oxygen and 90% nitrogen were applied in a plexiglas box for eight days to PH Group and PH + Bevacizumab Group. On day eight, RVPs were measured directly from the heart, and then animals were sacrificed. Heart and lung tissues were examined, and Fulton index was measured. Results: RVP, Fulton index, and tissue VEGF scores were significantly lower in PH + Bevacizumab group than PH group: median (ranges), RVP, mmHg, 37.8 (33.0-39.0) and 32.3 (28.0-35.0), p: 0.01; Fulton index: 0.30 (0.29-0.33) and 0.25 (0.24-0.26), p: 0.003; tissue VEGF scores: 5.1 (4.8-5.3) and 4.0 (3.8 4.1), p: 0.004, respectively. Conclusion: Bevacizumab, which is indeed an antineoplastic agent, might have a favorable effect on hypoxia -induced pulmonary hypertension. |
Databáze: | OpenAIRE |
Externí odkaz: |